In addition to TOP2A down-regulation, AbuHammad et al. [32] revealed that metabolizing genes (specifically CYP1A1 and CYP1A2) and other genes were crucial for cell cycle, apoptosis and DNA repair were involved in the development of doxorubicin resistance to breast cancer cells. The gene discussed is CYP1A2; the disease is breast carcinoma.